MARKET

LCTX

LCTX

Lineage Cell The
AMEX

Real-time Quotes | Nasdaq Last Sale

1.310
+0.060
+4.80%
After Hours: 1.300 -0.01 -0.76% 16:56 05/27 EDT
OPEN
1.250
PREV CLOSE
1.250
HIGH
1.310
LOW
1.205
VOLUME
350.55K
TURNOVER
0
52 WEEK HIGH
3.000
52 WEEK LOW
1.100
MARKET CAP
222.34M
P/E (TTM)
-4.5219
1D
5D
1M
3M
1Y
5Y
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of -500% and 56.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 22:05
Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 21:05
BRIEF-Lineage Cell Therapeutics Reports Q1 2022 Results
reuters.com · 05/12 21:02
Lineage Cell Therapeutics Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $5.20M Miss $7.32M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 300 percent decrease over losses of $(0.01) per
Benzinga · 05/12 20:20
Lineage Cell Therapeutics GAAP EPS of -$0.04 misses by $0.02, revenue of $5.24M misses by $3.66M
Lineage Cell Therapeutics press release (NYSE:LCTX): Q1 GAAP EPS of -$0.04 misses by $0.02. Revenue of $5.24M misses by $3.66M. Cash and Cash Equivalents of $78.1 Million as of March
Seekingalpha · 05/12 20:13
-- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q1 Revenue $5.2M, vs. Street Est of $8.9M
MT Newswires · 05/12 16:29
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 21:55
More
No Data
Learn about the latest financial forecast of LCTX. Analyze the recent business situations of Lineage Cell The through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
83.33%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LCTX stock price target is 6.40 with a high estimate of 8.00 and a low estimate of 5.00.
High8.00
Average6.40
Low5.00
Current 1.310
EPS
Actual
Estimate
-0.14-0.10-0.07-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 118
Institutional Holdings: 66.40M
% Owned: 39.12%
Shares Outstanding: 169.73M
TypeInstitutionsShares
Increased
29
919.96K
New
11
1.63M
Decreased
26
988.89K
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Alfred Kingsley
Chief Executive Officer/Director
Brian Culley
Chief Financial Officer
Kevin Cook
Senior Vice President
Gary Hogge
General Counsel/Secretary
George Samuel
Independent Director
Dipti Amin
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Anula Jayasuriya
Independent Director
Michael Mulroy
Independent Director
Angus Russell
No Data
No Data
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The Company has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.